NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF

Nanobiotix S.A.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 31, 2026

$21.08−0.22 (-1.03%)

Close on Oct 19, 2026

Nanobiotix S.A. cash flow statement

AnnualQuarterlyTTM

EUR USD

Millions of EUR, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31
Depreciation & Amortization	1.50	1.62	1.51	1.50	1.56	1.75	1.77	0.62
Stock-Based Compensation	3.54	4.30	3.22	3.17	3.20	2.92	4.32	1.87
Change in Accounts Receivable	0.84	-2.07	-0.81	-0.10	0.06	-0.05	-0.09	0.14
Operating Cash Flow	-33	-20	-12	-37	-30	-28	-41	-26
Capital Expenditures	-0.54	-0.85	-0.33	-0.09	-0.23	-0.10	-1.09	-0.42
Investing Cash Flow	-0.58	-0.96	-0.35	0.14	-0.24	-0.11	-1.46	0.07
Stock Issued	–	–	–	–	–	72	–	–
Debt Issued	43	0	0	0	0	10	14	16
Debt Repaid	-3.55	-3.08	-2.97	-3.64	-2.83	-0.25	-0.50	–
Financing Cash Flow	37	-5.14	47	-5.65	-5.18	112	41	15
Foreign Exchange Rate Adjustments	-0.40	0.09	-0.05	0.08	0.06	-0.06	0.03	0.05
Net Change in Cash	3.01	-26	34	-43	-35	84	-1.11	-11
Free Cash Flow	-34	-20	-13	-37	-30	-28	-42	-26

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -33.2%
Net margin: -73.5%
Return on equity, FY2025: –

Financial strength

Current ratio: 1.44
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 129.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –

Valuation ratios need the share price and fill in once daily prices are connected.